Brought to you by 
Relypsa nets $79.7mm through its IPO
03 Dec 2013
Executive Summary
Relypsa Inc. (cardiovascular and metabolic therapeutics) netted $79.7mm through the initial public offering of 7.8mm common shares (including a partial exercise of the overallotment) at $11. The company had originally planned to sell 6.9mm shares between $16-19. Some of Relypsa's current shareholders and one of its executive officers agreed to purchase a total of 1.8mm shares (about $19.9mm) through the financing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Relypsa nets $79.7mm through its IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice